The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Breyanzi to Join NHI List on May 19 at Post-CEA-Adjusted Kymriah Price
Celgene’s third-in-class CAR-T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) will be added to the NHI price list in Japan on May 19 at the same price as Kymriah’s (tisagenlecleucel) post cost-effectiveness assessment (CEA)-based adjustment price. Breyanzi’s listing was supported by…
To read the full story
Related Article
- Drug Pricing Rules to Be Applied to Breyanzi: Chuikyo
April 15, 2021
- Yescarta to Join NHI Price List on April 21, Gets CEA-Tweak from Get-Go
April 14, 2021
- Kymriah to Face 4% Price Cut in 1st CEA-Based Price Tweak, Yescarta Too
April 13, 2021
- Japan Approves 3rd CAR-T Cell Therapy, Celgene’s Breyanzi
March 23, 2021
REGULATORY
- OTC-Like Drugs Left in Limbo as Panel Debates Cost-Sharing without Clear Policy Signal
December 19, 2025
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
- Japan Moves LLP Payment Hike toward Political Call, Eyes 1/2 or Higher
December 18, 2025
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…